The tweet was deleted by the author.
But we saved everything 🙂.
Lineage Cell Therapeutics has announced its financial results for the first quarter of 2026, with an investor conference call set for 4:30 pm ET today to deliver a business update.
The company is expected to provide further insights into its recent performance and operational progress during the call. Investors and analysts will be watching for new developments relating to the firm's ongoing projects and future guidance. Additional details are available on the company website.
Lineage Cell Therapeutics previously shared 3-year trial data from its Phase 1-2a OpRegen study in geographic atrophy at the Retinal Therapeutics Innovation Summit. The company has been focused on advancing clinical programs across its pipeline. Recent updates reflect an ongoing emphasis on therapeutic development in age-related conditions.